Kyushu University Academic Staff Educational and Research Activities Database
Researcher information (To researchers) Need Help? How to update
Fujioka Yutaka Last modified date:2021.07.27





Homepage
https://kyushu-u.pure.elsevier.com/en/persons/yutaka-fujioka
 Reseacher Profiling Tool Kyushu University Pure
Country of degree conferring institution (Overseas)
No
Field of Specialization
neuroonchology
Outline Activities
Treatment of diseases in the field of neurosurgery. Education for residents. Clinical studies mainly on malignant brain tumors.
Research
Research Interests
  • liquid biopsy for malignant brain tumor
    keyword : liquid biopsy
    2018.04~2021.05.
Academic Activities
Papers
1. Yutaka Fujioka, Nobuhiro Hata, Yojiro Akagi, Daisuke Kuga, Ryusuke Hatae, Yuhei Sangatsuda, Yuhei Michiwaki, Takeo Amemiya, Kosuke Takigawa, Yusuke Funakoshi, Aki Sako, Toru Iwaki, Koji Iihara & Masahiro Mizoguchi, Molecular diagnosis of diffuse glioma using a chip-based digital PCR system to analyze IDH, TERT, and H3 mutations in the cerebrospinal fluid, Journal of Neuro-Onchology, 2021.01, Purpose
Conventional genetic analyzers require surgically obtained tumor tissues to confirm the molecular diagnosis of diffuse glioma. Recent technical breakthroughs have enabled increased utilization of cell-free tumor DNA (ctDNA) in body fluids as a reliable resource for molecular diagnosis in various cancers. Here, we tested the application of a chip-based digital PCR system for the less invasive diagnosis (i.e., liquid biopsy) of diffuse glioma using the cerebrospinal fluid (CSF).

Methods
CSF samples from 34 patients with diffuse glioma were collected from the surgical field during craniotomy. Preoperative lumbar CSF collection was also performed in 11 patients. Extracted ctDNA was used to analyze diagnostic point mutations in IDH1 R132H, TERT promoter (C228T and C250T), and H3F3A (K27M) on the QuantStudio® 3D Digital PCR System. These results were compared with their corresponding tumor DNA samples.

Results
We detected either of the diagnostic mutations in tumor DNA samples from 28 of 34 patients. Among them, we achieved precise molecular diagnoses using intracranial CSF in 20 (71%). Univariate analyses revealed that the World Health Organization (WHO) grade (p = 0.0034), radiographic enhancement (p = 0.0006), and Mib1 index (p = 0.01) were significant predictors of precise CSF-based molecular diagnosis. We precisely diagnosed WHO grade III or IV diffuse gliomas using lumbar CSF obtained from 6 (87%) of 7 patients with tumors harboring any mutation.

Conclusion
We established a novel, non-invasive molecular diagnostic method using a chip-based digital PCR system targeting ctDNA derived from CSF with high sensitivity and specificity, especially for high-grade gliomas..
Membership in Academic Society
  • The Japan Stroke Society
  • The Japan Neurosurgical Society
Educational
Educational Activities
Education for residents regarding neurosurgery in general.